Progenics Pharmaceuticals (PGNX) Stock Price, News & Analysis

Company Overview

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

Key Stats

• Today's Range: $3.94 to $4.79
• 50-Day Range: $4.10 to $4.10
• 52-Week Range: $1.89 to $6.37
• Volume: 34.93 million shs
• Average Volume: 1.16 million shs
• Market Capitalization: $355.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PGNX Stock Analysis - Frequently Asked Questions

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.03. The biotechnology company had revenue of $6.25 million for the quarter. Progenics Pharmaceuticals had a negative trailing twelve-month return on equity of 129.46% and a negative net margin of 180.28%.

What other stocks do shareholders of Progenics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Progenics Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Caterpillar (CAT), Exelixis (EXEL), IMAX (IMAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Citius Pharmaceuticals (CTXR).

Company Calendar

• Last Earnings: 5/07/2020
• Today: 7/03/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PGNX
• CIK: 835887
• Web: www.progenics.com
• Phone: 646-975-2500
• Fax: N/A
• Employees: 79
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.55 million
• Net Margins: -180.28%
• Pretax Margin: N/A
• Return on Equity: -129.46%
• Return on Assets: -53.23%

Debt

• Debt-to-Equity Ratio: 0.99
• Current Ratio: 2.12
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $34.99 million
• Price / Sales: 10.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 7.59

Miscellaneous

• Outstanding Shares: 86,597,000
• Free Float: N/A
• Market Cap: $355.05 million
• Optionable: Optionable
• Beta: 1.89